““Australia is #1 site to conduct Australia is #1 site to conduct clinical trials”clinical trials”

Summary of Economist Intelligence Unit Report:

Benchmarking Study of the Characteristics of the Australian and International

Pharmaceutical IndustriesSep 2005

““Australia is #1 site to conduct Australia is #1 site to conduct clinical trials”clinical trials”

Summary of Economist Intelligence Unit Report:

Benchmarking Study of the Characteristics of the Australian and International

Pharmaceutical IndustriesSep 2005

About the study

• Independent study conducted by Economist Intelligence Unit

• Commissioned by Australian Govt. Dept. Industry Tourism & Resources, Invest Australia, Victorian Govt. Dep. Innovation, Industry & Regional Development

• Benchmarked Australian Industry versus:– USA– UK– Germany– Japan– Singapore– India

Full report available at: www.industry.gov.au

Summary Scores Across Pharmaceutical Industry

Clinical Trials Benchmarking

0 2 4 6 8 10

Japan

Germany

India

UK

Singapore

USA

Australia

Aggregate Benchmark Scores

What is driving Australia’s performance?

Driven by low average cost per patient and high availability of research sites…

0 2 4 6 8 10

Japan

USA

UK

Germany

Singapore

Australia

India

Average cost per patient

0 2 4 6 8 10

India

Singapore

Germany

Japan

UK

USA

Australia

# sites per 100,000 pop.

$6,712 (USA) to $2,500 (India)

$3,984 (Australia)

25,000 (USA) to 11 (Singapore)

2,500 (Australia)

source: CentreWatch

…Good participation rates andhigh on-time completion rates…

0 2 4 6 8 10

India

Germany

Japan

Singapore

Australia

UK

USA

# patients in trials per 100,000 pop.

0 2 4 6 8 10

USA

Japan

Germany

UK

Singapore

Australia

India

% Studies completed on time

3,600,000 (USA) to 3,745 (India)

20,000 (Australia)

85% (India) to 10%(USA)

80% (Australia)

source: CentreWatch

…with a capacity to do more...#Phase I per 100,000 pop.

0 2 4 6 8 10

India

Japan

Australia

Germany

Singapore

UK

USA

0 2 4 6 8 10

India

Japan

Singapore

Germany

Australia

UK

USA

0 2 4 6 8 10

India

Japan

Germany

USA

Australia

Singapore

UK

0 2 4 6 8 10

India

Japan

Germany

Australia

USA

UK

Singapore

#Phase II per 100,000 pop.

#Phase III per 100,000 pop. #Other Phase per 100,000 pop.

Other includes Phase IV, medical device, bioequivalence

…and a quality workforcePharma Industry skilled

professionals per 100,000 LF.

0 2 4 6 8 10

India

USA

UK

Germany

Japan

Australia

Singapore

0 2 4 6 8 10

India

Germany

Japan

UK

USA

Singapore

Australia

0 2 4 6 8 10

India

Singapore

Japan

Australia

Germany

UK

USA

0 2 4 6 8 10

Japan

Germany

UK

USA

India

Australia

Singapore

#Graduate degrees per 100,000 LF.

Regulatory & Quality Systems Govt. Initiatives & Incentives

Other includes Phase IV, medical device, bioequivalence

Clinical Trial Activity

0

50

100

150

200

250

300

350

400

Phase I Phase II Phase III Phase IV& Other

2004

2005

• Pharma company sales in Australia $6b (1.2% of world market)

•93% prescription sales covered under PBS (Govt. funded)

•57% having some degree of local manufacture

• Export sales of Pharmaceuticals $2.4b

• 421 Core biotechnology companies (83 listed)

•Market cap $4.3b (ex. CSL)

• 612 Medical device companies (45 listed)

•Market cap $9.0b

Snapshot of Australian Pharma & Biotechnology Industry

Source: Bioindustry Review 2006

Australian Biotech sector is very active in forming alliances

36% North America

19% Europe12% Asia

28% Internal

3% NZ/Pacific

2% Africa

•112 alliances formed with US companies in 2005

•Australian Biotechs purchased 24 overseas companies

•112 alliances formed with US companies in 2005

•Australian Biotechs purchased 24 overseas companies

Source: Bioindustry Review 2006

• Australia is an excellent location for conducting clinical research

• Australia has a vibrant Biotech & pharmaceutical sector

• Australian companies want to work with international partners

Key Takeaways: